{
    "eid": "2-s2.0-85109827725",
    "title": "Ceritinib Efficacy and Safety in Treatment-Naive Asian Patients With Advanced ALK-Rearranged NSCLC: An ASCEND-4 Subgroup Analysis",
    "cover-date": "2021-03-01",
    "subject-areas": [
        {
            "@_fa": "true",
            "$": "Oncology",
            "@code": "2730",
            "@abbrev": "MEDI"
        },
        {
            "@_fa": "true",
            "$": "Pulmonary and Respiratory Medicine",
            "@code": "2740",
            "@abbrev": "MEDI"
        }
    ],
    "keywords": [
        "ALK",
        "ASCEND-4",
        "Ceritinib",
        "NSCLC"
    ],
    "authors": [
        "Daniel S.W. Tan",
        "Sarayut Geater",
        "Chong Jen Yu",
        "Chun Ming Tsai",
        "Te Chun Hsia",
        "Jun Chen",
        "Meng Chih Lin",
        "You Lu",
        "Virote Sriuranpong",
        "Cheng Ta Yang",
        "Paramita Sen",
        "Fabrice Branle",
        "Michael Shi",
        "Yi Long Wu"
    ],
    "citedby-count": 3,
    "ref-count": 27,
    "ref-list": [
        "Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer",
        "Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer",
        "Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK",
        "Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer",
        "Alectinib in ALK-positive, crizotinib-resistant, non-small-cell lung cancer: a single-group, multicentre, phase 2 trial",
        "Ceritinib in ALK-rearranged non-small-cell lung cancer",
        "Crizotinib versus chemotherapy in advanced ALK-positive lung cancer",
        "ALK inhibitors in non-small cell lung cancer: crizotinib and beyond",
        "Alectinib:. a novel second generation anaplastic lymphoma kinase (ALK) inhibitor for overcoming clinically acquired resistance",
        "FDA approval: ceritinib for the treatment of metastatic anaplastic lymphoma kinase-positive non-small cell lung cancer",
        "FDA broadens ceritinib indication to previously untreated ALK-positive metastatic NSCLC",
        "Zykadia prescribing information",
        "Activity and safety of ceritinib in patients with ALK-rearranged non-small-cell lung cancer (ASCEND-1): updated results from the multicentre, open-label, phase 1 trial",
        "Final overall survival and other efficacy and safety results from ASCEND-3: Phase II study of ceritinib in ALKi-naive patients with ALK-rearranged NSCLC",
        "First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study",
        "Pemetrexed combined with oxaliplatin or carboplatin as first-line treatment in advanced non-small cell lung cancer: a multicenter, randomized, phase II trial",
        "Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer",
        "A confidence interval for the median survival time",
        "Front-line treatment of ceritinib improves efficacy over crizotinib for Asian patients with anaplastic lymphoma kinase fusion NSCLC: the role of systemic progression control",
        "Alectinib versus crizotinib in untreated Asian patients with anaplastic lymphoma kinase-positive non-small-cell lung cancer (ALESIA): a randomised phase 3 study",
        "Alectinib (ALC) vs crizotinib (CRZ) in treatment-naive ALK+ non-small-cell lung cancer (NSCLC): Asian vs non-Asian subgroup analysis of the ALEX study",
        "Results of PROFILE 1029, a phase III comparison of first-line crizotinib versus chemotherapy in East Asian patients with ALK-positive advanced non-small cell lung cancer",
        "Crizotinib versus chemotherapy in Asian patients with ALK-positive advanced non-small cell lung cancer",
        "ASCEND-8: a randomized phase 1 study of ceritinib, 450 mg or 600 mg, taken with a low-fat meal versus 750 mg in fasted state in patients with anaplastic lymphoma kinase (ALK)-rearranged metastatic non-small cell lung cancer (NSCLC)",
        "Efficacy and safety of ceritinib (450 mg/d or 600 mg/d) with food versus 750-mg/d fasted in patients with ALK receptor tyrosine kinase (ALK)-positive NSCLC: primary efficacy results from the ASCEND-8 study",
        "ASCEND-8 pharmacokinetic, safety, and efficacy data for ceritinib 450 mg with food in patients with anaplastic lymphoma kinase-positive non-small cell lung Cancer: a clinical perspective",
        "Cost effectiveness of ceritinib and alectinib versus crizotinib in first-line anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer"
    ],
    "affiliation": [
        {
            "affiliation-city": "Taipei",
            "@id": "60031913",
            "affilname": "Chang Gung Memorial Hospital",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60031913",
            "affiliation-country": "Taiwan"
        },
        {
            "affiliation-city": "Basel",
            "@id": "60009968",
            "affilname": "Novartis International AG",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60009968",
            "affiliation-country": "Switzerland"
        },
        {
            "affiliation-city": "Chengdu",
            "@id": "60073509",
            "affilname": "West China School of Medicine/West China Hospital of Sichuan University",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60073509",
            "affiliation-country": "China"
        },
        {
            "affiliation-city": "Taipei",
            "@id": "60073385",
            "affilname": "National Taiwan University Hospital",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60073385",
            "affiliation-country": "Taiwan"
        },
        {
            "affiliation-city": "Guangzhou",
            "@id": "60069718",
            "affilname": "Guangdong Provincial People\u2019s Hospital of Southern Medical University",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60069718",
            "affiliation-country": "China"
        },
        {
            "affiliation-city": "Taichung",
            "@id": "60031941",
            "affilname": "China Medical University Hospital",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60031941",
            "affiliation-country": "Taiwan"
        },
        {
            "affiliation-city": "Singapore City",
            "@id": "60031809",
            "affilname": "National Cancer Centre, Singapore",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60031809",
            "affiliation-country": "Singapore"
        },
        {
            "affiliation-city": "Bangkok",
            "@id": "60022183",
            "affilname": "King Chulalongkorn Memorial Hospital",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60022183",
            "affiliation-country": "Thailand"
        },
        {
            "affiliation-city": "Taipei",
            "@id": "60013314",
            "affilname": "Veterans General Hospital-Taipei",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60013314",
            "affiliation-country": "Taiwan"
        },
        {
            "affiliation-city": "Tianjin",
            "@id": "60011715",
            "affilname": "Tianjin Medical University",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60011715",
            "affiliation-country": "China"
        },
        {
            "affiliation-city": "Hatyai",
            "@id": "60006314",
            "affilname": "Prince of Songkla University",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60006314",
            "affiliation-country": "Thailand"
        }
    ],
    "funding": [
        "Novartis Healthcare Pvt. Ltd.",
        "Bristol-Myers Squibb",
        "Eli Lilly",
        "Pfizer",
        "AstraZeneca",
        "GlaxoSmithKline",
        "Merck",
        "Novartis",
        "Roche",
        "Novartis Pharmaceuticals Corporation",
        "Boehringer Ingelheim",
        "Merck Sharp & Dohme",
        "Prince of Songkla University"
    ]
}